KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbCellera Biologics (ABCL) Invested Capital (2020 - 2026)

AbCellera Biologics filings provide 7 years of Invested Capital readings, the most recent being $938.1 million for Q1 2026.

  • Quarterly Invested Capital fell 9.08% to $938.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $938.1 million through Mar 2026, down 9.08% year-over-year, with the annual reading at $966.9 million for FY2025, 9.14% down from the prior year.
  • Invested Capital hit $938.1 million in Q1 2026 for AbCellera Biologics, down from $966.9 million in the prior quarter.
  • Across five years, Invested Capital topped out at $1.3 billion in Q3 2022 and bottomed at $938.1 million in Q1 2026.
  • Average Invested Capital over 5 years is $1.1 billion, with a median of $1.2 billion recorded in 2024.
  • The largest annual shift saw Invested Capital surged 32.85% in 2022 before it dropped 12.66% in 2025.
  • AbCellera Biologics' Invested Capital stood at $1.3 billion in 2022, then decreased by 5.85% to $1.2 billion in 2023, then dropped by 11.53% to $1.1 billion in 2024, then fell by 9.14% to $966.9 million in 2025, then fell by 2.98% to $938.1 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Invested Capital are $938.1 million (Q1 2026), $966.9 million (Q4 2025), and $964.0 million (Q3 2025).